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bstract
Clinically NFPA is currently the preferred term for designing all the pituitary adenomas which are not hormonally active (in other words, not
ssociated with clinical syndromes such as amenorrhea-galactorrhea in the context of prolactinomas, acromegaly, Cushing’s disease or hyperthy-
oidism secondary to TSH-secreting adenomas). They account for 15–30% of pituitary adenomas. Diagnosis is usually made either in the context of
ass effect due to a macroadenoma or, increasingly, fortuitously during imaging performed for some unrelated purpose; the latter case is known as
ituitary incidentaloma. Surgery is indisputably indicated in case of tumoral syndrome, but other aspects of NFPA (hormonal work-up, follow-up,
urrence, the special case of incidentaloma, or apoplexy) remain controver-nd especially postoperative follow-up, management of remnant or recial. The French Endocrinology Society (SFE) therefore set up an expert working group of endocrinologists, neurosurgeons, ophthalmologists,
euroradiologists, pathologists and biologists to draw up guidelines, at the 2012 SFE Congress in Toulouse, France. The present article presents
he guidelines suggested by this group of French-speaking experts.
 2015 Elsevier Masson SAS. All rights reserved.
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ésumé
Les adénomes hypophysaires non fonctionnels (AHNF) qui se définissent par défaut (ce ne sont ni des prolactinomes, ni des adénomes soma-
otropes responsables d’acromégalie, ni des adénomes corticotropes responsables de maladie de Cushing) représentent 15 à 30 % des adénomes
ypophysaires. Leur diagnostic est le plus souvent fait à l’occasion, soit d’un syndrome tumoral, lié à la présence d’un macroadénome, soit (et c’est
e plus en plus fréquent) de manière fortuite à l’occasion d’une imagerie faite pour une toute autre raison (ce sont les incidentalomes hypophysaires).
i l’indication chirurgicale ne fait aucun doute en cas de syndrome tumoral, d’autres aspects des AHNF (l’exploration hormonale, le suivi, en
articulier postopératoire, la conduite à tenir en cas de reliquat ou en cas de récidive, le cas particulier des incidentalomes, ou de l’apoplexie)
ont l’objet de discussions, qui ont amené la Société franc¸aise d’endocrinologie (SFE) à demander à un groupe d’experts (endocrinologues, neu-
ochirurgiens, ophtalmologistes, neuroradiologues, pathologistes et biologistes) de formuler des recommandations à l’occasion du Congrès de la
ociété franc¸aise d’endocrinologie qui s’est tenu à Toulouse en 2012. Cet article résume les recommandations proposées par ce groupe d’experts
rancophones.
 2015 Elsevier Masson SAS. Tous droits réservés.
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Clinically non-functioning pituitary adenomas (NFPA)
s currently the preferred term for designing all the pitu-
tary adenomas which are not hormonally active (in other
ords, not associated with clinical syndromes such as
menorrhea-galactorrhea, acromegalic features, hypercorticism
r hyperthyroïdism). Since 1979–1980, with progress in
mmunocytochemistry [1–3], it has been known that most “clin-
cally non-functioning” adenomas (chromophobe on classic
istology) actually secrete gonadotropins or are gonadotroph
ituitary adenomas. In 10% of cases, immunolabeling is neg-
tive (“null-cell adenoma”). Exceptionally, it may be positive
or GH, PRL, TSH or ACTH despite no secretion being found
n vivo; such cases are known as silent somatotroph, lactotroph,
hyrotroph or corticotroph adenomas.
Prevalence of pituitary adenoma is 80–100 cases per 100,000
f the population; NFPA accounts for 15–30% of these [4–6].
nnual incidence is 1 new case per 100,000 of the population [4].
At the present time, NFPA are diagnosed either in the con-
ext of mass effect related to the growth of a macroadenoma
r, increasingly, fortuitously during imaging for some unrelated
urpose; the latter case is known as pituitary incidentaloma [7,8].
Surgery is indisputably indicated in case of tumoral syn-
rome, but other aspects of NFPA (hormonal exploration,
ollow-up, and especially postoperative follow-up, management
f postoperative remnant or recurrence, the special case of
ncidentaloma, or apoplexy) remain controversial. The French
ndocrinology Society (SFE) therefore set up an expert working
roup of endocrinologists, neurosurgeons, ophthalmologists,
euroradiologists, pathologists and biologists to draw up guide-
ines, at the 2012 SFE Congress in Toulouse, France.
In the absence of prospective, randomized controlled studies,
he group could put forward only expert opinions, at best founded
n retrospective studies.
.  Biochemical,  neuroradiologic  and  clinical  assessment
f non-functioning  pituitary  adenomasPituitary macro-adenomas, whether discovered in the con-
ext of a mass effect or fortuitously, require various explorations
efore surgery can be indicated.
1
fRadiothérapie
The aim is to assess pituitary hormone secretion, looking
ither for hypersecretion (confirming non-functioning status) or
eficiency, which may require preoperative hormone replace-
ent therapy. The aim is also to provide the surgeon with good
ituitary imaging. Finally, inasmuch as indications for surgery
re closely dependent on optic pathway compression, optic path-
ay assessment is also indispensable, preoperatively and during
ollow-up.
The present guidelines are founded on a review of the litera-
ure, the details of which are given in the article by Raverot [9]
n the present Consensus document.
.1.  Diagnostic  hormonal  work-up  to  screen  for
athological  secretion
Half of the male and one-quarter of premenopausal female
atients with NFPA display increased levels of gonadotropins.
esponse of gonadotropins and free sub-units to TRH and GnRH
timulation tests are neither sensitive nor specific for the diag-
osis of the gonadotroph nature of the NFPA [9].
.1.1. Static  exploration
Preoperatively, systematic gonadotropin (LH, FSH) mea-
urement is recommended for allow preoperative diagnosis of
onadotroph adenoma (in case of increased levels of FSH and/or
H), but it does not affect the treatment or follow-up of NFPA.
Sub-unit α  measurement may be contributive, but should not
e systematic, especially as it is not covered by the French
ational Health Insurance System (unlisted analysis).
Prolactin (PRL) measurement is systematic in NFPA. In large
ituitary adenoma, PRL measurement should be performed with
/100 serum dilution, to avoid hook effect which may mask very
igh levels of PRL levels suggestive of prolactinomas.
Chromogranin A measurement is not recommended for diag-
osis or follow-up..1.2. Dynamic  testing
GnRH or TRH stimulation tests are not recommended
or diagnosis or follow-up of NFPA, being insufficiently
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ontributive and incurring a rare but serious risk of pituitary
poplexy.
.1.3. Screening  for  silent  pituitary  adenoma
“Silent” adenoma would seem to be of poorer prognosis (cf.
rticle by Cortet-Rudelli in the present Consensus document
10]) with more frequent recurrence. Silent pituitary adenoma
s defined by the absence of suggestive preoperative clinical
igns of secretion associated with positive immunolabeling of
he operated tumor for one or more hormones.
Only corticotroph silent adenoma can be detected pre-
peratively, with increase in ACTH levels and normal 8.00
.m. cortisol, or with absence of corticotroph deficit while
ll other pituitary hormones are deficient [9]. An overnight
examethasone-suppression test (1 mg dexamethasone at mid-
ight and measurement of cortisol and ACTH levels eight hours
ater) may be contributive (and is systematic in some centers),
s may be free urinary cortisol measurement.
In silent somatotroph adenoma, IGF-1 levels are by definition
ormal; otherwise, acromegaly should be diagnosed, even in
bsence of clear clinical signs (cf. Acromegaly Consensus [11]).
In silent lactotroph adenoma, prolactin assay is normal and
iagnosis is founded on positive tumor immunolabeling for PRL.
.2.  Screening  for  hypopituitarism
At time of diagnosis of non-functioning pituitary macro-
denomas, 60 to 85% of patients present at least one pituitary
eficiency, gonadotroph deficiency being the most prevalent
>80% of cases), followed by the somatotroph deficiency; thy-
otroph and corticotroph deficiencies are found in 20–50% of
ases [9].
.2.1. Hormonal  tests
Screening for corticotroph deficiency requires, for many
eams, a preoperative dynamic test: insulin tolerance test, ACTH
timulation test, CRH test or metyrapone test. Other teams only
erform measurement of morning cortisol: a level of >190 ng/ml
500 nmol/l) confirming corticotroph integrity, making dynamic
esting superfluous.
Screening for thyrotroph deficiency screening is based on
ree T4 measurement associated to third generation TSH assay.
Screening for gonadotroph deficiency in female subjects is
ased on clinical assessment, if necessary associated to plasma
onadotropin (LH and FSH) measurement. In male subjects,
lasma gonadotropin (LH and FSH) levels and total testosterone
easurement are required.
.2.2.  Assessment  at  diagnosis
Screening for pituitary gonadotroph, corticotroph and thy-
otroph deficiency is recommended at diagnosis of any pituitary
denoma, but only of macroadenoma. Preoperative detection of
eficiency enables treatment to improve clinical status ahead
f surgery or, if surgery has not been decided on, to monitor
ormonal status during follow-up, notably in case of corti-
otroph deficiency, and guides therapeutic decision-making (cf.
•rinologie 76 (2015) 239–247 241
ncidentaloma). Screening for somatotroph deficiency is not rec-
mmended at diagnosis.
.2.3.  Monitoring  of  pituitary  function  after  surgery
Corticotroph function should be assessed either in the imme-
iate postoperative period or at 4–6 weeks with systematic
ydrocortisone replacement in the interval. In case of deficiency,
urther exploration should be performed at least by 3 months
ostoperatively, to screen for late recovery.
Global pituitary function should be assessed 1–3 months
ost-surgery. If there is no postoperative deficiency, further
xploration is unnecessary unless there is progression in a tumor
emnant or occurrence of a recurrence. In case of postopera-
ive deficiency, 6–12 monthly monitoring is required to tailor
eplacement therapy.
If there is no postoperative deficiency, 6–12 monthly monitor-
ng is required if adjuvant radiation therapy is to be implemented.
Preoperative thyrotroph deficiency should be reassessed post-
peratively after at least 1 month’s interruption of thyroxine
herapy.
.3.  Pituitary  imaging
.3.1.  Neuroradiological  assessment  of  suspected  NFPA
Neuroradiological assessment of suspected NFPA is founded
n MRI, the reference examination for the sellar region.
.3.2. MRI  protocol
The MRI protocol should include:
 thin (≤3 mm) slices, high matrix, sagittal + coronal T1-
weighted sequences with and without gadolinium injection;
 coronal 3D volume assessment with reconstruction;
 T2-weighted coronal slices;
 volume acquisition is recommended; otherwise, very thin
slices are needed, with a reference plane (e.g., subcallosal).
.3.3. Typical  MRI  aspects  of  NFPA
Typical MRI aspects of NFPA are as follows:
 in macroadenoma, a mass centered on an enlarged sella tur-
cica, with T1/T2 signal varying according to necrotic and/or
hemorrhagic areas, possibly with fluid level;
 enhancement of the lesion is usually of low intensity.
The necrotic or hemorrhagic nature and extension of the
esion should be determined:
 superiorly, toward the optic pathways;
 laterally, in the cavernous sinuses, taking account of percent-
age tumoral inclusion of the internal carotid artery (arterial
diameter generally conserved) and visibility of medial cav-
ernous sinus veins;
 inferiorly, in the sphenoidal sinus, with sellar floor lysis and,
posteriorly, lysis of the clivus.
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The pituitary stalk, posterior lobe and healthy residual pitu-
tary parenchyma should be located.
.4.  Ophthalmologic  assessment  of  NFPA
Neuro-ophthalmologic exploration is one of the major deter-
inants of surgical indications. The present guidelines are based
n a literature review detailed in the article by Abouaf [12] in
he present Consensus document.
.4.1. Ophthalmologic  assessment
Ophthalmologic assessment should comprise:
 sensory evaluation: at least one measurement of visual acuity
(VA) and a visual field examination (VF), preferably cen-
tral static + peripheral kinetic. Anterior segment and fundus
examinations are also essential for interpreting the VA and
VF data; OCT is contributive but not essential for determining
visual prognosis;
 oculomotor evaluation: diplopia should be ruled out on inter-
view, checking the patient’s 9 gaze directions. This may be
completed by orthoptic examination and the Lancaster test.
.4.2. When  to  perform  ophthalmologic  exploration?
At diagnosis, within 3 months of surgery, and ahead of any
adiation therapy (RT) in case of adenoma abutting or compress-
ng the optic chiasm.
Subsequent follow-up depends on visual involvement and
rogression, and on scheduled RT.
.  Surgical  treatment  of  non-functioning  pituitary
denomas
No effective medical treatment being available, as in the case
f prolactinoma or somatotroph adenoma, first-line treatment of
FPA is surgical, usually with a trans-sphenoidal approach.
The present guidelines for surgery are based on a literature
eview detailed in the article by Castinetti [13] in the present
onsensus document.
.1.  Indications  for  surgery
.1.1.  In  symptomatic  macroadenoma
.1.1.1.  Visual  disorders.  Visual disorders are an indication for
urgery, urgency depending on the degree of visual impairment.
ecovery correlates with duration and severity of VF defect;
mprovement is reported in about 80–90% of cases, up to 1 year
ost-surgery [13].
.1.1.2.  Hypopituitarism.  Hypopituitarism should be taken
nto account for deciding to treat surgically, as postoperative
ecovery is uncertain (around 30% of cases), with a 5–10% risk
f aggravating or inducing hypopituitarism. The risk of onset of
iabetes insipidus is less than 5%.
.1.1.3. Mass  effect.  Pituitary adenoma cannot be incriminated
n headache until all other causes have been ruled out (possibly
2
trinologie 76 (2015) 239–247
fter neurologic consultation). Disabling headache implicating
he adenoma may thus be an indication for non-emergency
urgery, but the patient should be warned that causality is
nproven and relief cannot be guaranteed.
In large adenoma without visual disorder, the decision is
ade on an individual basis and is founded on the kinetics of
rogression on two successive MRI scans.
.1.2.  Surgical  indications  for  particular  situations
Indications in older subjects (aged 65 to 75–80 years).
hey are identical to those in younger subjects if comorbid-
ty and anesthesia risk are well assessed (ASA score [American
ociety of Anesthesiology: http://www.asahq.org]). The prin-
ipal indication is visual involvement. Surgery, if decided on,
hould preferably be trans-sphenoidal, in order to limit the risk
f complications. In “physiologically elderly” subjects, sur-
ical risk is elevated and indications should be weighed on
 case-by-case basis, with the sole objective of optic chiasm
ecompression.
Indications in patients taking anti-platelets or anticoagulants.
reatment with anti-vitamin K increases the risk of spontaneous
erebral hemorrhage 7–10-fold and interruption, with use of hep-
rin in the interval, is recommended 5 days ahead of surgery,
o achieve a normal INR (international normalized ratio); anti-
itamin K will be reinitiated within 7–14 days. Anti-platelets
ncrease the risk of postoperative hematoma, but preoperative
nterruption is associated with increased morbidity and mor-
ality, especially in drug-eluting stent bearers, and requires the
greement of a cardiologist, 5 days before surgery for aspirin and
deally 10 days for clopidogrel, with resumption theoretically
–10 days post-surgery.
.1.3. Asymptomatic  micro-  or  macro-adenomas
Asymptomatic micro- or macro-adenomas are generally dis-
overed fortuitously on MRI performed for some other reason.
anagement and surgical indications are dealt with in section 5,
he particular case of non-functioning pituitary incidentaloma.
.1.4. NFPA  developing  during  pregnancy
In case of NFPA developing during pregnancy and inducing
isual disorder, surgery is mandatory. If there is no chiasmal
ompression during pregnancy, delivery can be vaginal. Breast-
eeding is in no way contraindicated.
.2.  Surgical  technique
.2.1.  Endoscopy  versus  microsurgery?
More than the technique as such, it is the neurosurgeon expe-
ience that is essential in the management of pituitary adenomas,
nd the choice is at the discretion of the surgeon. Endoscopy
s probably preferable to microscopy, providing better con-
rol of lateral and superior extension for an identical rate of
omplications but this has not been clearly demonstrated [13]..2.2. Technical  speciﬁcities
The choice between the various approaches (2-step surgery,
rans-sphenoidal extended approach, trans-cranial approach) is
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t the surgeon’s discretion, according to experience and adenoma
xtension. Approaches are limited to specific types of adenoma,
ccording to extension. More specific techniques (neuronavi-
ation, intraoperative MRI) may be used if the surgeon judges
ecessary and they are available.
.  Pathologic  diagnosis  of  non-functioning  pituitary
denomas
The pathology report should include certain information
ndispensable to diagnosis and subsequent management, as
etailed in the appendix to the article by Castinetti in the present
onsensus document [13]. Teamwork between endocrinologist,
eurosurgeon and pathologist is required: final pathologic diag-
osis of NFPA should also take into account imaging data and
ntraoperative findings, to assess tumor size and invasiveness
oward the cavernous and/or sphenoidal sinuses.
Immunohistochemistry allows to determine the nature of the
denoma: gonadotroph (FSH, LH, SU, chromogranin A
ntibodies) or silent somatotroph and/or lactotroph (GH, PRL
ntibodies) or corticotroph adenoma (ACTH antibodies, cytok-
ratin). The pathology reports also need to establish proliferation
tatus by systematically testing three types of cell-cycle markers:
i67, mitosis index and p53 [13].
.  Postoperative  management  of  pituitary
on-functioning  pituitary  adenomas
Despite progress in neurosurgery, the size and frequent inva-
iveness of NFPA often result in partial resection, and the
emnant is susceptible to regrow (at 10 years, half have regrown)
10]. Moreover, even when resection is total, recurrence is
ossible, even if are (30% at 10 years) [10]. In either case,
omplementary treatment (surgical revision, radiation therapy,
edical treatment) may be indicated. The following guidelines
re founded on the literature data detailed in the article by Cortet-
udelli in the present Consensus document [10].
.1.  Postoperative  follow-up  of  NFPA
.1.1.  Follow-up  imaging
Postoperative radiologic monitoring is essential in NFPA due
o the frequent lack of any clinical symptoms despite progres-
ion. It is best performed on MRI, with pituitary CT only in
ase of contraindications. Reproducibility is indispensable to
ood follow-up, and is ideally achieved by volume acquisition
ith 3D reconstruction. If the latter is unavailable, scans should
e taken under constant technical conditions with an identical
eference plane: e.g., coronal slices perpendicular to the sub-
allosal plane. It is important to provide the neuroradiologist
ith the preoperative MRI scan, surgical report and reference
ostoperative MRI, for purposes of interpretation. The imaging
rotocol comprises thin (2–3 mm) slices: T1-weighted sagittal,
1-weighted coronal T1 before and after gadolinium injection,
nd T2-weighted coronal or T1-weighted axial.
Regarding the frequency of postoperative MRI, immediate
xamination is not systematic but may be prescribed for
t
t
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uspected postoperative complications or in case of early
evision surgery within the first days. Otherwise, the first MRI
s at 3 or 6 months; a 6-month interval minimizes difficulties of
nterpretation due to postoperative remodeling. A second MRI
s systematically performed one year post-surgery. These two
RIs serve as references for subsequent follow-up.
Precise interpretation of the reference postoperative MRI is
rimordial, to detect residue and thus risk of progression. In the
bsence of adenomatous residue, MRI is repeated annually for 5
ears, then at 7, 10 and 15 years. In the absence of clinical signs,
dentifiable residue or suspect images, systematic radiological
ollow-up may then be terminated. In case of adenomatous rem-
ant or suspect image, MRI is repeated annually for 5 years and
hen every 2 or 3 years in the absence of progression, and the
chedule is redefined on a case-by-case basis according to tumor
ize, remnant distance from the optic pathways or any doubt as
o remnant progression. Longer intervals incur a risk of loss to
ollow-up, requiring special vigilance, recurrence usually occur-
ing 1–5 years after surgery but sometimes later, at more than
0 years [10].
At each control, it is essential to check the new image against
he postoperative references: gradual increase in residue size
ight be overlooked if the new MRI is compared only with
he preceding one and not with the postoperative reference, as
denoma growth is often slow and hard to discern from one year
o the next.
.1.2. Ophthalmologic  follow-up
In case of preoperative ophthalmologic abnormality, a check-
p is made at 3 months post-surgery, comprising VA, VF, fundus
nd oculomotor examination, and repeated every 6 months until
aximal improvement is achieved, especially if initial disorder
as severe or contraindicated driving; such contraindications
hould be reviewed regularly during follow-up. Surveillance
ntervals may then be lengthened.
In the absence of visual impairment at the first postoperative
isit, follow-up can stop if there is no suprasellar remnant threat-
ning the optic pathways. In case of radiation therapy, prolonged
nnual follow-up is mandatory, especially after hypofractionated
r single-dose radiation therapy, to screen for radiation-induced
omplications, which may occur several years post-treatment.
.1.3. Hormonal  follow-up
Biochemical hormonal assessment at 3 months post-surgery
ocuses on recovery of preoperative pituitary deficiencies and
n the definitive nature of deficiencies found postoperatively.
xploration is then repeated to adapt, if necessary, replacement
herapies in case of functional alarm signs or increased size of
ny residue. The frequency of pituitary deficiency following RT
f whatever type requires twice-yearly reassessment as above.Deficits, obviously, require replacement. GH treatment is at
he physician’s discretion, in the light of the fact that the litera-
ure now supports the absence of any stimulation of remnant or
nduction of recurrence.
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.2.  When  is  simple  surveillance  indicated?
.2.1.  In  the  absence  of  identiﬁable  adenomatous  remnant
r in  case  of  suspect  image
Prolonged regular surveillance is recommended, the risk of
omplications associated with reoperation being lower than that
f recurrence and/or recurrence-related complications.
.2.2. In  case  of  remnant
Two options are available: simple surveillance or adjuvant
herapy. Decision-making, in agreement with the patient, taken
n a multidisciplinary approach including neuroradiologist, neu-
osurgeon, radiotherapist and endocrinologist, is founded on the
ollowing:
 morphology: size, limits, relation to optic pathway, invasive-
ness toward cavernous sinus;
 pathology findings: immunohistochemistry, Ki67, p53, mito-
sis index;
 remnant progression;
 patient age and history and ability for prolonged regular
surveillance;
 hypopituitarism;
 availability of and experience with the various adjuvant treat-
ments in the center.
.3.  What  are  the  options  in  case  of  recurrence  or  remnant
rogression?
.3.1.  Second  surgery
Indications for reoperation of residual NFPA should take into
ccount the initial surgical report and the size and location of
he remnant.
Surgery is indicated for progressive remnant accessible to
omplete resection (limited by cavernous sinus invasion); for
ymptomatic optic pathway compression or to obtain 3–5 mm
afety margins between superior tumoral dome and optic path-
ay for complementary RT; in case of progression after RT.
Surgery may also be initially planned as 2-step: intrasel-
ar resection, followed by second surgery after the fall of the
uprasellar contingent.
Remodeling of classical landmarks (sphenoidal rostrum,
phenoidal sinus septum) and poorer differentiation of intrasellar
issues may hinder surgery. Some teams recommend intraoper-
tive neuronavigation in such cases, but this is controversial.
.3.2. Radiation  therapy
.3.2.1.  Pituitary  radiation  therapy  techniques.  Fractionated
onformal RT delivers high-energy X photons, improving depth
endering and reducing radiation field penumbra. 3D location
nd dosimetry, multiple non-coplanar beams, intensity mod-
lation and multi-slice fan-beam collimators have improved
omplex volume targeting, providing considerable progress.
otal dose ranges between 45 and 50 Gy, fractionated in 25
essions of 1.8–2 Gy [10].
Radiosurgery delivers radiation in a single session. The objec-
ive is to superimpose the target and the chosen reference
n
s
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sodose. The dose diminishes rapidly beyond the target, max-
mizing sparing of adjacent healthy structures. This requires an
nvasive stereotactic frame, to achieve precise positioning within
 mm, a high-resolution imaging system, and 3D dosimetry. The
evices used are the Gamma-Knife (201 Co60 sources on a hemi-
phere) and linear accelerator (LINAC). The marginal dose is
sually 13–16 Gy in NFPA. This type of RT is feasible only if
he target volume is clearly defined, small (<2–3 cm on the long
xis) and sufficiently remote from the optic pathways to ensure
8 Gy irradiation of the chiasm and optic nerves.
Fractionated stereotactic RT associates the ballistic precision
nd multiple beam entries of radiosurgery to the principle of
ealthy tissue radioprotection by fractioning. The total dose
s 45–50 Gy by 1.8–2 Gy fractions. CyberKnife is a miniatur-
zed accelerator with a robotic arm, enabling hypofractionated
tereotactic RT (3–9 sessions, depending on the team) with a
on-invasive contention system based on the technical and dosi-
etric principles of radiosurgery.
Proton therapy is not widely available and thus little used for
FPA.
.3.2.2.  When  is  radiation  therapy  indicated  in  NFPA?.  The
fficacy of postoperative RT in NFPA is clearly undisputable,
hatever the technique and whether treatment is first-line or
ost-surgical. The various types of RT show comparable effi-
acy in terms of tumoral control, and the choice between them
epends on residue size, delineation and relation to adjacent neu-
al structures, the particular center’s technical experience and the
atient’s availability for follow-up [10].
Benefit, however, needs to be weighed against known side-
ffects, and especially RT-induced hypopituitarism, which is
 frequent complication of all the RT techniques. Vascular
omplications and rare secondary brain tumors can be expected
o be less frequent with hypofractionated or single-dose stereo-
actic RT, but follow-up is as yet too short for affirming that this
s true.
Systematic postoperative RT is not indicated following com-
lete resection, given the low rate of recurrence. In case of
ignificant residual tumor, RT should be considered, taking
ccount of risk factors for regrowth, patient age and history
nd presence of hypopituitarism. In most cases, the first-line
ttitude can be regular surveillance, postponing RT until recur-
ence is confirmed. First-line RT may be indicated in case of
igh growth potential and if the risk of hypopituitarism is no
onger a major problem (notably, if the patient already displays
ypopituitarism).
.3.3. Medical  treatment
The discovery of type D2 dopaminergic receptors and SST3
nd SST2 somatostatin receptors within NFPAs, plus in vitro
ndings, have led to propose the use of dopamine agonists and
omatostatin analogs in patients with NFPA. At present, none
f these therapies has demonstrated sufficiently frequent sig-
ificant efficacy in reducing tumor volume to be recommended
ystematically in case of failure of surgery.
Temozolomide is an oral alkylating agent that proved effec-
ive in pituitary carcinoma and aggressive adenoma (mainly
ndoc
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actotroph or corticotroph). Low tumoral expression of O6-
ethylguanine DNA methyltransferase (MGMT) is associated
ith good temozolomide response. Low expression of MGMT
as shown to be more frequent in recurrent than non-recurrent
FPA, suggesting that temozolomide may also be useful as
escue therapy against very aggressive NFPA.
.  The  particular  case  of  non-functioning  pituitary
ncidentaloma
Pituitary incidentaloma is a pituitary lesion discovered fortu-
tously on brain imaging (CT, MRI or PET) performed for some
ther reason.
When <10 mm on its longest axis, it is known as “pituitary
icroincidentaloma”, and if >10 mm as “pituitary macroinci-
entaloma”.
In the great majority of cases, fortuitous discovery leads to
anagement that may differ from that of symptomatic pituitary
denoma. The following guidelines are founded on the literature
ata detailed in the article by Galland in the present Consensus
ocument [14].
.1.  Initial  assessment  of  microincidentaloma
.1.1.  Microincidentaloma
Microincidentaloma should undergo clinical assessment by
n endocrinologist to screen for hormonal hypersecretion (signs
f hyperprolactinemia, acromegaly or Cushing’s syndrome) and
ny syndromic or familial context.
It should also undergo limited biochemical assessment:
RL and IGF-1 measurement (or overnight dexamethasone-
uppression test if Cushing’s disease is suspected). Screening
or cortisol hypersecretion is reserved for clinical Cushing’s
yndrome. Screening for hypopituitarism is not recommended.
.1.2. Ophthalmologic  assessment
Ophthalmologic assessment is not recommended.
.1.3.  MRI
MRI centered on the pituitary gland should be performed if
he imaging underlying discovery was not so centered.
.2.  Initial  assessment  of  macroincidentaloma
Hormonal, neuroradiologic and visual assessment is similar
o that performed in symptomatic non-functioning macroade-
oma (see section 1 – Biochemical, neuroradiologic and clinical
ssesment of NFPA, above).
.3.  Management  of  non-functioning  pituitary
icroincidentaloma
Attitude depends on microadenoma size.
s
i
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.3.1.  Diameter  of  <5  mm
If the largest diameter is <5 mm, neither radiologic nor hor-
onal surveillance is recommended, and the attitude should be
eassurance.
.3.2. Diameter  of  ≥5  mm
If the largest diameter is ≥5 mm, initial control MRI is rec-
mmended, at 6 months for some teams and 12 months for
thers, repeated at 2 years to detect any progression. In case
f non-progression, surveillance can be stopped. In rare cases of
rogression, annual MRI should guide management: continued
urveillance, or surgery.
.4.  Management  of  non-functioning  pituitary
acroincidentaloma
Attitude again depends on macroadenoma size, and also on
roximity to the optic chiasm.
.4.1.  Adenoma  remote  (we  suggest  ≥5  mm)  from  the  optic
hiasm
MRI at 1 year accompanied by hormonal biochemical assess-
ent looking for hypopituitarism is recommended. In case of
bsence of progression, surveillance intervals may be lengthened
o 2-yearly MRI. Annual hormonal biochemical assessment
hould be maintained in case of progression. Visual assessment
VA, VF) should be performed for lesions coming abutting the
ptic chiasm during follow-up. In case of progression, surgical
esection may be considered.
.4.2.  Adenoma  close  to  the  chiasm
Surgery is not formally indicated but should be discussed with
he patient, taking into account the natural history of NFPA and
he low morbidity associated with surgery, and the need for the
atient’s compliance with surveillance, any plans for pregnancy,
nd risk factors for apoplexy, etc.
If surgery is not decided on, control MRI should be performed
t 6 months, completed by hormonal and visual assessment. MRI
nd hormonal assessment are thereafter continued annually, with
isual evaluation every 6 months.
In case of visual involvement, hypopituitarism or tumoral
rogression, treatment strategy is similar to that proposed for
ymptomatic NFPA (see section 2 – Surgical treatment of NFPA,
bove).
.  The  particular  case  of  pituitary  apoplexy
Pituitary apoplexy is a serious acute complication of (usu-
lly non-functioning) pituitary adenoma, characterized by acute
eadache syndrome, possibly associated with visual disorder
ue to chiasmal compression or oculomotor involvement. In
ore than two-thirds of cases, it is associated with pituitary,
nd especially corticotroph, deficiency [15].
Historically, apoplexy was a systematic indication for
urgery; the publication of reports of spontaneous clinical
mprovement, however, has led some authors to propose a more
onservative attitude in some selected patients [16].
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The issues in pituitary apoplexy are thus the following: should
urgery be systematic or not? When should surgery be per-
ormed, if indicated?
In case of abstention, are high-dose corticosteroids useful?
.1.  Multidisciplinary  management,  including  systematic
edical treatment
.1.1.  Management  of  apoplexy
Management of apoplexy should be multidisciplinary: neuro-
urgeon, neuroradiologist, endocrinologist and ophthalmologist.
dmission to a neurosurgery or endocrinology department in
mmediate proximity to a neurosurgery center is recommended.
.1.2. Glucocorticoid  treatment
As corticotroph deficit is almost always present, hydrocor-
isone replacement (if possible, after sampling for hormonal
ssay) should be initiated immediately; it is vital for the patient. It
hould, for example, consist of IV hydrocortisone hemisuccinate
0–100 mg every 8 hours, then followed by oral administration.
.2.  Indications  for  surgery  in  case  of  apoplexy
.2.1.  Surgery
Surgery is indicated in case of altered consciousness or recent
r worsening severe visual defect.
In such cases, surgery should be performed as soon as possi-
le, although an experienced pituitary surgeon may be preferred.
.2.2. Isolated  oculomotor  palsy
Isolated oculomotor palsy is an indication for surgery accord-
ng to some surgeons but not others.
.3.  Indications  for  conservative  management  (simple
urveillance without  immediate  surgery)
.3.1.  Conservative  management
Conservative management needs to be covered by high-dose
V or oral glucocorticoid treatment and clinical and ophthalmo-
ogic surveillance.
Conservative management is indicated in case of contraindi-
ations to surgery (unfavorable risk/benefit ratio).
Conservative management is indicated in case of stable or
ong-standing moderate visual defect.
Conservative management is indicated in case of isolated
culomotor palsy.
Conservative management is indicated on condition that
hange of strategy is feasible, with conversion to surgery in the
bsence of rapid improvement (within days).
.4.  Patients  with  pituitary  macroadenoma  close  to  the
ptic chiasm  should  be  warned  of  the  risk  of  apoplexy
clinical signs,  at-risk  situation).4.1.  Neuroradiologic  evaluation  in  pituitary  apoplexy
In acute-phase apoplexy (within the first hours after the
eginning of signs and symptoms), CT is highly contributive [rinologie 76 (2015) 239–247
o diagnosis in case of hemorrhage. MRI may prove non-
ontributive in case of hemorrhage in the acute phase (T1 and
2 isosignal).
After that very early phase, MRI is the imaging technique of
hoice.
.  Conclusion
NFPA are usually diagnosed in a context of signs and
ymptoms related to mass effect. Treatment, except in case
f contraindication or particular situation, is thus basically
urgical, after detailed hormonal, neuroradiologic and ophthal-
ologic assessment. Resection, generally via a trans-sphenoidal
pproach, needs to be performed by a neurosurgeon with large
xperience in pituitary surgery, to maximize the chances of com-
lete resection and minimize complications. In case of remnant
frequent in large and often invasive adenomas), surveillance
s required to avoid unnecessary adjuvant treatment (usually
adiation therapy) in case of absence of growth. After com-
lete resection, NFPA may recur in some patients. The attitude
ow recommended is also to propose surveillance to these
atients, radiation therapy being proposed in case of growth of
he relapsing tumor. Non-functioning pituitary incidentalomas
ay, because of their fortuitous discovery, require a different
pproach to symptomatic pituitary adenoma, especially when
hey are small or remote from the optic pathways.
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